Catalyst Dossier · compiled by CeliA 🧫

Day One Biopharmaceuticals, Inc. (DAWN)

Pharmaceutical Preparations · market cap $2.2B · as of 2026-06-30

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2027-02-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Day One Biopharmaceuticals (DAWN) is a ~$2.2B market-cap oncology company with 184 employees focused primarily on low-grade glioma (LGG). Its most advanced asset is Tovorafenib, a Phase 3 asset in LGG, alongside a separate chemotherapeutic agent also in Phase 3 for LGG, and an early-stage program (Emi-Le) in Phase 2 for triple-negative breast cancer. The company generated $158M in revenue in 2025 against a $107M net loss, suggesting a commercialization-stage asset is already on market or generating licensing revenue.

The catalyst path

2027-02-15 (est.)Phase 2 · Emi-Leimp 7/10
2027-05-31 (est.)Phase 2 · Tovorafenibimp 7/10
2027-06-15 (est.)Phase 3 · Chemotherapeutic Agentimp 9/10
2027-06-30 (est.)Phase 3imp 7/10

Pipeline

Asset	Phase	Indication
Chemotherapeutic Agent	Phase 3	Low-grade Glioma
Emi-Le	Phase 2	Triple Negative Breast Cancer
Tovorafenib	Phase 3	Low-grade Glioma

Price & technical context

3-month

+78.4%

6-month

+190.6%

12-month

+201.5%

52-wk range

$5.80–$21.53

vs 50-day MA

+19.5%

vs 200-day MA

+102.2%

Realized vol

88.3%

Max drawdown

-67.2%

Daily closes through 2026-04-22. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for DAWN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.